Lead Product(s) : Avacopan
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ChemoCentryx plans to discuss the results with the U.S. Food and Drug Administration as it has obtained evidence of avacopan’s ability to improve renal function, being well-tolerated in C3G patients to date.
Product Name : Tavneos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 21, 2020
Lead Product(s) : Avacopan
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Propagermanium
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
DIMERIX’s DMX-200 Posts Strong Results in Kidney Disease Trial
Details : Primary and secondary endpoints met in the Phase 2a study of DMX-200 in FSGS patients, 86% of patients demonstrated a reduction of proteinuria with DMX-200 versus placebo.
Product Name : DMX-200
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 29, 2020
Lead Product(s) : Propagermanium
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable